依达拉奉对急性脑梗死患者血清SOD、S-100β蛋白的影响

Effect of edaravone on the level of SOD and S-100 β in patients with acute cerebral infarction

目的探讨依达拉奉对急性脑梗死患者血清SOD、S-100β蛋白的影响。方法将同期收治的71例急性脑梗死患者随机分为治疗组(n=36)和对照组(n=35)。2组均予丹参、肠溶阿司匹林常规治疗,对照组以0.9%氯化钠溶液250 mL+丹参注射液30 mL、0.9%氯化钠溶液250 mL+胞二磷胆碱注射液250 mg静滴,1次.d-1;治疗组在此基础上予依达拉奉注射液30 mg溶于0.9%氯化钠溶液100 mL中静滴,2次.d-1。2组均治疗2个疗程,共14 d,分别于治疗前后记录神经功能缺损评分(CSS量表),评定临床疗效,计算有效率,并于第1、3、7、14日检测血清超氧化物歧化酶(SOD)、S-100β蛋白的水平。结果 2组患者SOD经治疗后均逐渐下降,但治疗后治疗组血清SOD水平均明显高于对照组(P<0.05);2组患者S-100β蛋白均在第3日达到峰值,但治疗组水平明显低于对照组(P<0.01),其后均逐渐降低,2周后S-100β蛋白下降到相同的水平(P>0.05);治疗第14日后2组CSS评分指数较治疗前均明显减少(P<0.01),但治疗组评分少于对照组(P<0.05);2组经治疗后,治疗组有效率高于对照组(P<0.05)。结论依达拉奉能显著改善急性脑梗死患者的神经功能,减少急性脑梗死患者血清SOD消耗量,降低S-100β蛋白水平,对急性脑梗死的神经元有保护作用,其机制为清除自由基、减轻脑缺血及再灌注损伤。

Objective To investigate the effect of edaravone on the level of SOD and S-100 β protein in patients with a-cute cerebral infarction.Methods A total of 71 patients with acute cerebral infarction were randomly divided into a therapy group（n=36） and a control group（n=35）.Based on the routine treatment of Danshen and conventional aspirin,the control group was administered 0.9% sodium chloride solution 250 mL＋ Danshen 30 mL,0.9% sodium chloride solution 250 mL＋citicoline 250 mg,intravenous injection,once daily.The therapy group was administered edaravone 30 mg＋ 0.9% sodium chloride solution 100 mL,twice daily.Both treatments lasted 2 courses,14 d.The neurological deficit score（CSS Scale）to assess the clinical efficacy was recorded before and after the treatment and the contents of serum SOD and S-100 β were detected after the treatment at 1,3,7,and 14 d.Results SOD level in both groups gradually declined after the treatment,but the SOD level in the therapy group was significantly higher than that in the control group（P0.05）.S-100 β in both groups reached the peak on day 3,but S-100 β of the treatment group was significantly lower than the control group（P0.01）.S-100 β gradually reduced,and returned to the same level after 2 weeks（P0.05）.After 14 d CSS index score was significantly lower than before（P0.01）,and score of the treatment group was lower than the control group（P0.05）,and the effective rate of the therapy group was higher than the control group（P0.05）.Conclusion Edaravone can significantly improve the nerve function in patients with acute cerebral infarction,reduce serum SOD consumption in patients with acute cerebral infarction,lower S-100 β protein levels,and have a protective effect on neurons.The mechanism may be free radical scavenging and reducing cerebral ischemic as well as reperfusion injury.